Pila Pharma AB Analyst Coverage
Redeye Equity Research
Sweden (coverage ceased February 28, 2023
Analyst: Filip Einarsson
Rights Issue Outcome
[November 22, 2022]
Q3’22: Funding in Focus
[October 26, 2022]
Initial Results from the 13-week safety study
[October 12, 2022]
Q2’22: An Aspiring TRPV1 Platform Company
[August 26, 2022]
Tox Studies Initiated
[June 30, 2022]
Adjusting for Capital Injection
[May 03, 2022]
Q1’22: New Project Revealed
[April 26, 2022]
Initiation Coverage
[December 17, 2021]
AktieInfo Equity Research
Denmark
—
Analyst: John Stihøj
Analyse: Årsregnskab 2025
[March 13, 2026]
Analyse – Halvårsrapport 2024
[September 30, 2024]
Analyse: Halvårsrapport 2025
[September 23, 2025]
Analyse: Årsregnskab 2024
[March 24, 2025]
Analyse – Halvårsrapport 2024
[September 30, 2024]
Indledende Analyse: Årsrapport 2023
[April 2, 2024]
Carlsquare Equity Research
Sweden
—
Analyst: Niklas Elmhammer
Initiation of coverage (ENG)
[June 3, 2026]